Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials

被引：0
|
作者：
Nacho Castejón
Kristin Khalaf
Quanhong Ni
Jesús Cuervo
Donald L Patrick
机构：
[1] LA-SER Outcomes,Department of Health Services
[2] C/ Azcárraga 12 A 33010 Oviedo,undefined
[3] Allergan Inc.,undefined
[4] Allergan Inc.,undefined
[5] University of Washington,undefined
来源：
Health and Quality of Life Outcomes | / 13卷
关键词：
Overactive bladder; Urinary incontinence; Utility assessment; Health-related quality of life; I-QOL;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 42 条
  • [41] Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial
    Mitcheson, Henry D.
    Samanta, Suvajit
    Muldowney, Karen
    Pinto, Cathy A.
    Rocha, Beatriz de A.
    Green, Stuart
    Bennett, Nathan
    Mudd, Paul N., Jr.
    Frenkl, Tara L.
    EUROPEAN UROLOGY, 2019, 75 (02) : 274 - 282
  • [42] Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis
    Korman, Neil J.
    Sofen, Howard
    Fretzin, Scott
    Rich, Phoebe
    Zhao, Yang
    Herrera, Vivian
    Nyirady, Judit
    Williams, Nicole
    Mordin, Margaret
    Tyring, Stephen
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (05) : 384 - 389
12345